We recommend that the choice of ESA is based on local availability and cost of ESAs. (1B)
Rationale
Many studies have been published comparing different ESA products against each other when used at different dosing intervals, by different routes of administration and in different patient groups. (1, 2) All the available products are efficacious when administered according to the manufacturers’ recommendations. The choice of ESA will be dependent upon the clinician and patient agreeing a management plan and local supply arrangements (2, 3).
References
- Chung EY, Palmer SC, Saglimbene VM, Craig JC, Tonelli M, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2023 Feb 13;2(2)
- Arantes, L. H., Jr, Crawford, J., Gascon, P., Latymer, M., Launay-Vacher, V., Rolland, C., Scotte, F., & Wish, J. (2018). A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia. Critical reviews in oncology/hematology, 129, 79–90.
- National Collaborating Centre for Chronic Conditions, Royal College of Physicians. Chronic kidney disease: assessment and management. 2021. National Institute for Clinical Excellence.